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Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma
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Summary We determined the circulating level of bioactivity for skeletal muscle proteolysis-inducing factors
(PIF) in the blood samples from cancer patients whose body weight loss was greater than 10%. The level of
bioactivity was estimated by measurement of tyrosine release from isolated rat diagphragm muscles incubated
with an ultrafiltered fraction of plasma or serum proteins containing molecules from 0 to 25 kDa in molecular
weight. Significant levels of bioactivity were detected in 25 of the 50 cancer samples. No activity was found in
18 of the samples from healthy human blood donors. The ability of 13 of the cancer samples to induce muscle
proteolysis was significantly inhibited by incubation of muscles in presence of indomethacin (10gM). The
neutralisation of 12 of the cancer samples with the antibodies to recombinant human interleukin-I (IL-1), a
and P forms, partially abrogated the activity in five samples. These results suggest that the accelerated
breakdown of proteins induced by the cancer plasma factors is at least in part mediated by IL-1 in
cooperation with other active factors not yet defined. Additionally, we have shown that the increased
breakdown of proteins induced by PIF in the crude supernatant derived from activated mouse peritoneal
macrophages is prevented by the treatment of muscles with either indomethacin or quin-2 (1 juM). These
observations provide indirect evidence for a possible causal relationship between the production of PIF and
the body-weight loss of cancer patients.
The loss of body weight and development of cachexia are
common and easily recognisable signs that are associated
with cancer and several other chronic and inflammatory
diseases (Lawson et al., 1982). In response to neoplastic and
infectious diseases, a variety of cells, including macrophages
and lymphocytes, secrete cytokines which are capable of
altering the host's metabolism. These cytokines include
interleukin-1 (IL-1) (Dinarello, 1988) and tumour necrosis
factor/cachetin (TNF-a) (Beutler & Cerami, 1986). TNF-a
has been suggested to contribute to the development of the
complex metabolic changes leading to cachexia because it
suppresses lipoprotein lipase activity (Kawakami & Cerami,
1981; Semb et al., 1987); and rodents given daily injections of
this cytokine (Stovroff et al., 1988; Mahony et al., 1988';
Tracey et al., 1988), or inoculated with a TNF/cachectin-
secreting tumour (Oliff et al., 1987) progressively decline food
intake and develop severe body wasting. Recent studies have
revealed that mobilisation of amino acids from skeletal mus-
cle tissue of patients undergoing infectious illness, trauma or
sepsis is mediated by a hormone-like protein called proteo-
lysis-inducing factor (PIF) (Clowes et al., 1983). This protein
secreted by activated monocytes may be IL-1 or a IL-i-like
peptide (Baracos et al., 1983; Dinarello et al., 1984). It has
also been shown that prostaglandin E2 production was in-
creased by these macrophage secretory products and an
inhibitor of the cycloocygenase pathway, indomethacin,
partially attenuated the stimulation in skeletal muscle protein
degradation (Baracos et al., 1983). The concept of PIF as
either IL-1 or an IL-1-derived peptide fragment is open to
question since recent reports have shown that recombinant
IL-1 proteins do not stimulate mouse or rat muscle
catabolism in vitro (Moldawer et al., 1987; Goldberg et al.,
1988). Likewise, the involvement of TNF-a on catabolism of
proteins has been demonstrated by some studies in vivo (War-
ren et al., 1987; Flores et al., 1989; Mahony & Tisdale, 1988;
Fong et al., 1989) and in vitro (Mahony et al., 1988; Charters
& Grimble, 1989) and refuted in others (Kettelhutt & Gold-
berg, 1988; Moldawer et al., 1987; Rofe et al., 1987; Michie
et al., 1988). Nevertheless, the capacity of IL-1 and TNF to
cause either weight loss or anorexia in animals has often been
noted (Stovroff et al., 1988; Hellestein et al., 1989; Fong et
al., 1989; Michie et al., 1988; Mahony & Tisdale, 1988). The
mechanisms underlying these processes are incompletely
understood.
It is presently unknown whether muscle proteolysis-
inducing factors are involved on the cachectic wasting pro-
cess in cancer patients. The current report was therefore
undertaken to evaluate the circulating bioactivity levels of
these agents in the plasma proteins of weight-losing patients
with different types of cancer at various phases of disease.
Parallel experiments were carried out to further explore the
ability to elicit the intracellular protein breakdown in the
isolated rat diaphragm muscle of macrophage secretory pro-
ducts present in crude supernatants and preparations of
recombinant human interleukin-l- and p.
Materials and methods
Patients selection
Blood samples were collected from a population of patients
with a variety of active and advanced cancers when admitted
to either surgical or clinical treatment in the Clinic Hospital
of the Faculty of Medicine of Sao Paulo and the A. C.
Camargo Hospital. In this study the patients were classified
according to the type of cancer and both clinical evidence
and patient complaint of weight loss greater than 10% of
baseline body weight. Samples of serum or plasma were
collected from 50 patients (32 male and 18 female, aged
13-83 years) with the following histological diagnoses: breast
cancer four, prostate cancer three, rectal adenocarcinoma
one, lung cancer four, metastatic adenocarcinoma one, pan-
creatic cancer one, gastric cancer seven, multiple myeloma
two, lymphoma ten, acute myelogenous leukaemia nine,
oesophageal cancer one, skin cancer one, head and neck
cancer one, coriocarcinoma one, pharynx cancer one, and
central nervous system cancer three. Either plasma or serum
were also taken from 18 normal blood bank donors (11 male
and seven female, aged 18-40 years) who were deemed to be
in good health on the basis of physical examination and
blood analysis carried out at the time of donation.
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Preparation ofplasma and serum samplesfor assays
The blood was drawn into EDTA or plain tubes and plasma
or serum samples were separated by centrifugation at 800g
for 20 min. Subsequently, samples intended for muscle
proteolysis assay were prepared by ultrafiltration for 1-2 h
at 800g, 4°C using membrane cones, type CF25 (Amicon
Corp., Danvers, MA) which have >95% retention for
molecules above 25 kDa. The ultrafiltrates containing
molecules with lower than 25 kDa molecular weight were
aliquoted and frozen at - 70°C until used. To examine TNF-
a activity, plasma and serum samples were dialysed for 24 h
against 0.9% NaCl using membrane tubing (Spectrum Medical
Inc., Annex, LA) with molecular weight cut-off of 3.5 kDa.
Animals
Young male and female Wistar rats (80-100 g) and adult
male and female Swiss mice (25-30 g) were provided by the
animal housing of Butantan Institute. For the muscle proteo-
lysis assays, rats were deprived of food for 24 h.
Reagents
Indomethacin (Sigma Chemical Co., St. Louis, MO) was
dissolved in 0.1 M Tris buffer (pH 8.0) as a stock solution of
1 mM. Arachidonic acid (Sigma) was added to the incubation
medium after mild alkaline treatment. Quin-2/AM, quin-2/
acetoxymethyl ester (Amersham Corp., Arlington Heights,
IL) was dissolved in dimethylsulphoxide (DMSO) as a stock
solution of 1 mm. Recombinant human interleukin-l-a
(Gubler et al., 1986) was a kind gift from Dr Peter
Lomedico, Hoffmann-La Roche (Nutley, NJ). The specific
activity of this preparation was determined to be 109 U mg
'
protein using the D1O.G4.1 cells assay. Recombinant human
interleukin-l-P (Auron et al., 1984) with a specific activity of
5 x 108 U mg-' protein, as measured in the DIOS cell pro-
liferation assay (Dinarello et al., 1986a), and polyclonal rab-
bit anti-sera to rhIL-1-a and rhIL-1-P (Dinarello et al.,
1986b) were generously provided by Dr Charles A. Dinarello,
Tufts University/New England Medical Center (Boston, MA).
To neutralise IL-1 activity, the mixture of antibodies to
IL-1-< and IL-1-P (final concentration of each one 0.05%)
plus the serum/plasma samples were incubated at 4°C for
24 h. One control assay was carried out using rabbit non-
immune sera.
Net protein catabolism assay in the rat diaphragm muscle
Following anaesthesia (ether), rats were killed by cervical
dislocation. Both hemidiaphragm muscles (lacking ribs) were
promptly dissected and cut into two pieces (one used in
paired control and the other in a test assay). Each quarter of
muscle was rinsed, blotted, weighted (30-40 mg), and placed
into a stoppered borosilicate glass flask (15 ml size) contain-
ing 1.5 ml of Krebs-Ringer-Bicarbonate buffer, pH 7.4, sup-
plemented with glucose 5 mM, branched chain amino acids
[0.85 mM isoleucine, 0.5 mM leucine and 1 mM valine], insulin
0.1 Uml', HEPES 15mM, polymyxin B 201tgml-', and
equilibrated with a 95% 02/5% CO2 gas mixture. The mus-
cles were pre-incubated for 1 h at 37°C in a shaking water
bath. Thereafter, they were transferred into fresh media con-
taining either crude supernatants from macrophage culture,
low molecular weight fraction of human serum/plasma pro-
teins, or recombinant human IL-1 proteins, and incubated
for further 2 h. The conditioned media were analysed for
tyrosine concentration according to the fluorometric method
of Waalkes and Undernfriend (1957). The results were ex-
pressed as pM of tyrosine per mg of muscle tissue (wet
weight) per 2 h. In the cancer samples assays, the net protein
catabolism was calculated as the difference between the total
of tyrosine released into the incubating medium and the
initial tyrosine content into the plasma samples, determined
in a separate test-tube. The net protein catabolism rate to
each particular sample (average of six replicates) was com-
pared with the paired control and the result expressed as the
difference (A) between the means ± s.e.m. (Figures 2, 3 and
4). In the assay to examine IL-1 activity, 1.0% FCS was
added to the incubation buffer to prevent protein adherence
to the glass.
Isolation and culture ofperitoneal macrophages and
preparation ofcrude supernatants
The peritoneal leukocytes were harvested from the mouse
cavity after injection of 10ml RPMI 1640 medium (Gibco
Laboratories, Grand Island, NY). The cell suspension was
washed in culture medium and collected by centrifugation at
800g for 15 min. The cell pellet was diluted in RPMI
medium that contained 10% foetal calf serum (FCS) and
antibiotics and approximately 5 x 106 cells ml-1 were
inoculated into 24-well microplates at a volume of 0.5 ml per
well and incubated in a humidified CO2 incubator at 37°C for
4 h. The non-adherent cells were removed by gently rinsing
the wells with medium and the adherent cells were subse-
quently incubated overnight in complete medium. The next
day, the medium was aspirated and fresh medium containing
1 jigml-' LPS (LPS E. coil 055:B5, Sigma) or 10ngml-'
PMA (Phorbol 12-myristate 13-acetate-4-O-methyl ether,
Sigma) were added and cells returned to incubator for an
additional 24 h. Parallel control cultures were performed in
which only complete medium was added. The culture media
were collected, centrifuged and the cell-free supernatant
stored at - 70°C until analysis.
Other assays
TNF content in the crude supernatants from activated
macrophages and in a low molecular weight fraction of
plasma proteins from cancer patients were assayed using the
L929 mouse fibroblast cell cytotoxicity assay (Flick &
Gifford, 1984). Briefly, approximately 50 x 104 L929
cellsml-' were suspended in culture medium and dispensed
into 96-well microtitre plates, and grown overnight at 37°C in
a 5% C02-95% air atmosphere. Subsequently, the media
were removed and replaced with RPMI 1640 containing
2.5% FCS, supplemented with 5iLg ml-' of actinomycin D
(control) or serial dilutions of rhTNF (kindly provided by
Genentech Inc., South San Francisco, CA) or the test sam-
ples. The plates were incubated for a further 18-20 h.
Viability of cells was measured by staining for 3-4 h with
500pgml-' of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tet-
razolium bromide (MTT) (Sigma), followed by removal of
medium and lysis of cells with 0.1 ml isopropanol. The
photometric measurement was performed at 560/690 nm in a
Bio-Rad model 3550 microplate reader. The TNF-a content
in a sample, expressed in Uml-', was calculated by com-
parison to a calibration curve established with rhTNFa. One
unit of TNF was defined as the concentration of TNF neces-
sary to achieve 50% cell cytotoxicity. IL-1-P and TNF-x were
also determined by a radioimmunoassay as described
elsewhere (Endress et al., 1988).
Statistics
All data are expressed as mean ± s.e.m.. Differences in the
tyrosine release between experimental groups were evaluated
using the Student's t-test for unpaired comparisons. The
standard error of the difference between the groups was
determined by the formula: s.e.m. = square root (s.d.,2/
n, + s.d.22/n2).
Results
Effects ofa low molecular weightfraction ofthe human plasma
or serum proteins on the rat diaphragm muscle netprotein
catabolism
For comparison, in Figure 1 we show the effects induced by
the addition of a low molecular weight fraction, which con-MUSCLE PROTEOLYSIS-INDUCING FACTOR IN CANCER 707
tain molecules ranging from 0 to approximately 25,000
molecular weight, derived from plasma or serum samples ofa
group of 18 normal subjects and a group of 50 cancer
patients on net protein catabolism of the rat diaphragm
muscles. As seen in Figure 1, none of 18 serum/plasma
samples from healthy human volunteers induced net protein
catabolism. These samples caused inhibition of release of
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Figure 1 Effects of a fraction containing proteins with molecular
weight ranging from zero to 25,000 obtained from plasma and
serum samples of normal human donors (NH) and cancer
patients (CP) on net protein catabolism of the rat diaphragm
muscles. The results are expressed as percentage ofchanges in the
concentrations of tyrosine release mg ' of muscle 2 h- I between
the muscles incubated with buffer plus 10% of a particular
sample (represent by circles) and the muscles incubated with
buffer only (represented,by horizontal line). The circles below and
above the line represent the samples which caused a reduction or
an increase of tyrosine release statistically significant (P <0.05),
whereas the circles around the line did not cause a significant
change when compared with respective controls.
tyrosine from rat diaphragm muscles which were statistically
significant (P<0.05), as compared with control muscles
incubated with buffer only. By contrast, in 50% (25/50) of
the protein fractions of cancer patients a significant stimul-
tory effect was observed (P <0.05). No significant effect on
muscle protein catabolism (equal at paired control) was
observed in 44% (22/50) of samples analysed. An inhibitory
effect was also observed in 6% (3/50) of cancer samples
(P <0.05). Equivalent levels of bioactivity were detected in
the assays with the proteins fractions obtained from either
plasma or serum samples. To test whether the cancer plasma
protein fraction had similar effect in other muscles,
experiments were performed with intact rat soleus muscles
with their tendon attached to a support at resting length. The
net protein catabolism ofintact muscles was also significantly
increased by the addition of a low molecular weight fraction
of cancer plasma proteins. This was observed with three of
the six samples examined.
Indomethacin inhibits the rat diaphragm muscle netprotein
catabolism inducedbyplasmaproteinsfrom cancerpatients
The rat diaphragms incubated in presence of indomethacin
10 zM did not alter the basal catabolism rate, as compared
with controls (Table I). The inhibitory effect caused by
plasma proteins from normal human subjects was also not
altered by the presence of indomethacin, whereas the incre-
ment in the skeletal muscle protein catabolism induced by
arachidonic acid (Rodemann & Goldberg, 1982) was com-
pletely abolished (data not shown). Subsequently we
examined whether the increase in the intracellular protein
breakdown caused by a group of plasma/serum cancer
samples could be also blocked by indomethacin. As seen in
Figure 2, the rates of protein catabolism were significantly
reduced. Furthermore, as result ofthe treatment in nine of 13
samples, rather than stimulation, we observed inhibition of
the net protein breakdown.
Effect ofneutralising antibodies to IL-I on the activity of
proteolysis-inducingfactors inplasmaproteins ofcancer
patients
To determine the involvement of either IL-1-% or P as pos-
sible mediators of net protein catabolism in the plasma pro-
teins from cancer patients, 12 samples were treated with a
combination of the specific antibodies to the IL--1< and P (at
Table I Inhibition by indomethacin and quin-2 of the rat diaphragm muscle net
protein catabolism induced by proteolysis-inducing factors in crude supernatants
from mouse peritoneal macrophage cultures
Treatment
Buffer
Indomethacin
Buffer
Supernantant
Indomethacin
Supernantant +
Indomethacin
Buffer
Quin-2a
Buffer
Supernantant
Quin-2
Supernantant +
Quin-2
Net protein catabolism
pMtyr mg-'mm 2h-'
500 ± 30
520± 19
505 ± 16
706 ± 43*
660 ± 41
565 ± 20*
216 ± 9
219± 12
182 ± 9
229 ± 18*
240± 9
185± 15*
Stimulation Inhibition
% over control % under control
+4
+40
- 14
+ I
+26
-23
Values are the means ± s.e.m. for sextuplicates incubating from one of three similar
experiments. Indomethacin (1OpM) and quin-2 (I FM) were added in both
pre-incubation and incubation media. 'The effect of quin-2 and related assays were
examined in the final I h of incubation. The crude supernantant obtained from
PMA-stimulated mice peritoneal macrophage culture were added to incubation buffer
at a dilution 1:10. *P <0.05 vs paired control.
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Figure 2 Effects of a low molecular weight fraction of plasma
proteins from cancer patients on net protein catabolism of the rat
diaphragm muscle incubated in the absence or presence of 10 JLM
indomethacin. The bars represent the difference ± s.e.m. between
the average of pM tyrosine release mg-' of muscle 2 h-' from the
muscles incubated with buffer plus 10% of a particular sample
and the average of the muscles incubated with buffer only.
*P <0.05, §P <0.01 and ¶P <0.001 vs paired control. tP<0.05
vs indomethacin treated.
0.05% final dilution for each antibody) and examined in
simultaneous experiments. In the presence of these anti-
bodies, the capacity to induce net protein catabolism in seven
of 12 samples (58%) were quite similar in both experimental
conditions (Figure 3). The bioactivity of samples 15, 16, 21,
24 and 25 were partially neutralised. The percentage of
inhibition by antisera on the bioactivity of those samples
were 56, 22, 37, 82, 41%, respectively. The changes caused by
the treatment were significantly different (P >0.05) than the
respective controls (P <0.01).
Recombinant human IL-I increases net protein catabolism in
the rat diaphragm muscle
Figure 4 shows the results of two representative experiments
from a group of assays in which we observed a variable
pattern of responses induced by recombinant forms of
human IL-1 on the rat diaphragm muscle net protein cata-
bolism assay. RhIL-l1- (Figure 4a) increased the rat muscle
net protein catabolism in a dose-dependent manner. It was
statistically significant (P <0.05) at concentrations of 100,
200 and 300ngml-'. This regular profile of activity was
verified in five assays and not repeated in another two out of
seven assays undertaken. RhIL-l-P (Figure 4b) caused an
increment in the rat muscle net protein catabolism at lower
concentration. A significant difference (P <0.05) was
detected for the concentration l0ngml-'. The maximum
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Figure 3 Bioactivity of a low molecular weight fraction of
plasma proteins from cancer patients without or with immune
neutralisation by rabbit polyclonal antibodies against IL-1-
(0.05%) and IL-l-P (0.05%) on net protein catabolism in the rat
diaphragm muscle. The bars represent the difference ± s.e.m.
between the average of pM tyrosine release mg-
1 of muscle 2 h- I
from the muscles incubated with buffer plus 10% of a particular
sample and the average obtained in the muscles incubated with
buffer only. *P <0.05, §P <0.01 and rP <0.001 vs paired con-
trol. tp<0.05 vs IL-I treated.
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Figure 4 Net protein catabolism of the rat diaphragm muscles
incubated in the presence of recombinant human IL-1-o and
IL-I-P. The bars are the difference ± s.e.m. between the average
of pM of tyrosine release mg-' of muscle 2 h-' of the muscles
incubated with buffer plus a selected concentration of IL-l and
the average obtained in the muscles incubated with buffer only.
*P<0.05, §P<0.01 and ¶P<0.001 vs paired control.
enhancement of approximately 300pM of tyrosine mg-' of
muscle 2 h-' was obtained with the concentration of
100 ng ml1 ' ofrhIL-I-P. The profile of activity to rhIL-1-P as
seen in Figure 4b was obtained in four separate assays and
bell-shaped distributions were observed in six assays. The rat
diaphragm muscle protein catabolism was not significantly
stimulated by IL-1-P in five other assays.
IL-J-P, but not TNF-c, is present in a low molecular weight
fraction ofplasma proteinsfrom cancer patients
The TNF proteins were not detected in a fraction that con-
taining molecules with lower than 25 kDa obained from
cancer plasma samples using L929 cell biossay and the TNF
radioimmunoassay. IL--1-P reactive proteins were detected by
radioimmunoassay in the plasma/serum of six out of 20
samples analysed. The concentrations ranged from 200 to
380pgml-'. These samples however were not included in
muscle proteolysis biossay study, even though the criteria
used to select this patient population were the same used for
the current study.
Proteolysis-inducingfactors in crude supernatants ofactivated
macrophages increase net protein catabolism in the rat
diaphragm muscle
The average of increases in net protein catabolism of muscles
incubated in presence of the crude supernatant samples from
activated macrophage culture ranged from 30 to 63%. No
activity was detected in the samples from unstimulated
macrophages cultures (data not shown). Subsequently, as an
approach to determine the involvement of calcium ions and
prostaglandins in activating protein catabolism by these fac-
tors, the muscle preparations were treated with quin-2, an
intracellular calcium chelator, or indomethacin. As seen in
Table I, whereas the presence of these compounds did not
influence significantly the basal protein catabolism of muscle
tissue in the control assays, the acceleration ofprotein break-
down and consequent release of tyrosine in the incubating
medium within 2 h-incubation period (indomethacin) or 1 h-
incubation period (quin-2) was significantly inhibited.
Discussion
A variety of biologic activities may be responsible for in-
creased body-weight loss in cancer patients, presumably as
the result of interactions ofendogenous factors and/or cancer
products with their specific target cells (Theologides, 1979;
Norton et al., 1985). The data in the present study provide
strong support for the concept that the protein turnover rates
in skeletal muscles of weight-losing cancer patients are
influenced by circulating factors produced in response to a
disease state. Indirect evidence for the phenomenon was
observed in experiments in vitro by using rat skeletal muscles
a b
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as the target of these circulating mediators, and by measuring
the rate of increase in the tyrosine concentration of the
conditioned medium as an indicator of intracellular protein
catabolism. A significant level of activity for these factors
was detected in 50% of samples from a group of 50 patients,
whereas no evidence of such activity was found in plasma
protein samples from healthy human volunteers. The
mechanism by which these mediators alter the protein turn-
over rates; whether by inducing protein degradation or by
inhibiting protein synthesis or even both activities, remains to
be elucidated. According to previous studies (Fulks et al.,
1975; Baracos et al., 1986) showing that the increment of
tyrosine release from rat diaphragm muscle preparations
reflects the net protein degradation, it is most likely that the
effect observed is at least in part due to the activation of
intracellular protein breakdown. However, such in vitro
observations disagree with the results of Lundholm et al.
(1981), which indicate that the net loss of muscle tissue in
tumour-bearing animals is more dependent on depressed pro-
tein synthesis than breakdown. A third and less likely
explanation for the phenomenon is that these factors are
causing an enhanced release of tyrosine from the muscle
pools.
The biochemical nature of these mediators and their
source, whether from tumour or host cells, remains to be
determined. In a recent study by Beck and Tisdale (1987)
evidence was presented that a 'muscle tissue proteoteolytic
factor' is produced by a murine adenocarcinoma of the colon
called MAC 16, a tumour selected for its ability to induce
severe cachexia in mice. Further evidence that polypeptide
factors with similar biological activity are produced by
activated macrophages is presented here (Table I)
and elsewhere (Dinarello et al., 1984; Goldberg et al., 1988;
Moldawer et al., 1987).
IL-1 and TNF, the prominent monocyte/macrophage pro-
ducts can be produced by a variety of tumour cell lines
(Busson et al., 1987; Beutler & Cerami, 1986; Spriggs et al.,
1987; Dinarello, 1988). Elevated circulating levels of TNF
and IL-1 have been found in patients suffering chronic infec-
tion, parasitic and malignant diseases (Beutler & Cerami,
1986; Dinarello, 1988; Moldawer et al., 1988). In fact, we
detected moderate levels of IL-1-P in six of the 20 plasma
samples from cancer patients. IL-1 and an IL-1-derived frag-
ment may be the causative agents of accelerated skeletal
muscle protein catabolism in febrile patients (Clowes et al.,
1983; Baracos et al., 1983; Dinarello et al., 1984). In agree-
ment with these reports, it was shown here that recombinant
human IL-1-o and IL-1-P can stimulate protein catabolism in
a rat-diaphragm muscle bioassay. However, we are unable
yet to provide a definitive explanation for the variability in
the dose-response effect of some assays. We have hypo-
thesised that tissue-released factors might act indirectly by
perturbing cellular physiology and responsiveness of muscle
tissue to IL-1, as previously described (Wallach et al., 1988).
Despite these facts, the finding that the treatment of cancer
samples with the combination of antibodies against human
IL-1-< and P partially inhibited the muscle proteolysis-
inducing activity present in five of the 13 cancer plasma
samples examined (Figure 3) has further substantiated our
evidence that IL-1 can lead muscle tissue to enhance intracel-
lular proteolysis.
TNF, or TNF and IL-1 in a coordinated fashion, can elicit
metabolic changes in skeletal muscle tissue (Warren et al.,
1987, Mahony et al., 1988; Fong et al., 1989; Flores et al.,
1989). As a consequence of its active molecular weight being
higher than 25 kDa, TNF was not detected in the ultra-
filtered fraction of plasma/serum proteins from cancer
patients. The results suggest instead that another active
factor(s), whose molecular weight is lower than 25 kDa, is
acting to accelerate skeletal muscle proteolysis (Figure 3). In
fact, recent studies have also suggested that another
unidentified protein(s) appears to be responsible for
accelerating skeletal muscle protein degradation in vitro
(Moldawer et al., 1987; Goldberg et al., 1988). Thus, it is
most likely that the induction of muscle protein catabolism
which accompanies inflammatory disease is not an effect of a
single cytokine, but rather may be mediated by combinations
of both cytokines and the classical protein metabolism
regulatory hormones: catecholamines, glucagon and
glucocorticoids.
Indomethacin, a prostaglandin synthetase inhibitor,
decreases the activity of proteolysis-inducing factors and
other stimulus leading to in vitro skeletal muscle protein
breakdown (Baracos & Goldberg, 1986; Rodemann & Gold-
berg, 1982; Baracos et al., 1983). In fact, PGE, and PGE2
can affect directly the protein breakdown in skeletal muscle
through their capacity to activate the lysosomal enzymes
(Rodemann & Goldberg, 1982; Mahony et al., 1988). Inter-
estingly, IL-1 by itself or in combination with either polypep-
tide growth factors or TNF stimulate the local production of
PGE2 in many tissues and cell types (Last-Barney et al., 1988;
Dinarello, 1988). Together these findings support our results
which show that indomethacin is a potential inhibitor of
skeletal muscle protein catabolism activated by polypeptide
factors into the plasma samples from cancer patients and by
macrophage secretory products.
One particular experiment in this study has shown that the
incubation of the rat diaphragm muscle with quin-2, a cal-
cium chelating agent, prevents the acceleration of protein
breakdown induced by proteolysis-inducing factors in condi-
tioned medium from macrophage culture. This finding is
consistent with previous reports demonstrating that changes
in the extracellular and intracellular calcium concentration
appear to play a major role in this process (Rodemann &
Goldberg, 1982; Baracos et al., 1986). Interestingly, studies
have indicated that myofibrillar and cytoskeletal proteins in a
variety of cells are degraded by a group of cytosolic calcium
dependent proteases named calpains (Pontremoli & Melloni,
1986). Thus, the activation of these enzymes may represent
one mechanism by which proteolysis inducing factors pro-
duce their effects.
In summary, this study shows that biologically active fac-
tors in the plasma of cancer patients and conditioned
medium from activated macrophages can enhance in vitro rat
skeletal muscle protein catabolism. Indomethacin and quin-2
decreased the activity of these factors suggesting that the
activation of protein breakdown and subsequent release of
tyrosine is followed by the synthesis of prostaglandins and
calcium mobilisation. Although the chemical nature these
molecules has yet to be determined, our evidence is consistent
with previous studies suggesting that the acceleration of pro-
tein catabolism induced by circulating factors might con-
tribute to weight loss and progressive wasting of skeletal
muscles in human cancer.
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